Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NXPtfJdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBTWM2OD1yLkCwNFI5PyEQvF2= NH\CdW9USU6JRWK=
LC-2-ad M3fie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMECwN|E4KM7:TR?= M1m2e3NCVkeHUh?=
RL95-2 NFvwc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInKSJZKSzVyPUCuNFAxPjZ6IN88US=> NFG1OlJUSU6JRWK=
MZ1-PC M1Gxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMECwO|I6KM7:TR?= M{fINXNCVkeHUh?=
TE-8 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMECxNVch|ryP M2rWcXNCVkeHUh?=
SW954 NV7hR4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\CdGJ2UUN3ME2wMlAxOTF7IN88US=> MXPTRW5ITVJ?
TE-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjoeVJKSzVyPUCuNFAyOjNizszN NUjRd|FGW0GQR1XS
PSN1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fsNGlEPTB;MD6wNFE{KM7:TR?= MmfrV2FPT0WU
MOLT-4 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3CTWM2OD1yLkCwNVQ6KM7:TR?= NIO5XmVUSU6JRWK=
697 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXCb2djUUN3ME2wMlAxOTVizszN MmrBV2FPT0WU
ETK-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi0WZpKSzVyPUCuNFAyPTJizszN NEf1PIhUSU6JRWK=
TE-10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[zdWlEPTB;MD6wNFE2PCEQvF2= NV;HdJJzW0GQR1XS
HUTU-80 M1Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnxOFd5UUN3ME2wMlAxOTZ6IN88US=> NFrhTmxUSU6JRWK=
NTERA-S-cl-D1 M{m3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XFVmlEPTB;MD6wNFIxQSEQvF2= MoDVV2FPT0WU
MFH-ino Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMECyOlgh|ryP NW\tUGNrW0GQR1XS
IA-LM M{fSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrkTJlKSzVyPUCuNFAzQCEQvF2= MXTTRW5ITVJ?
MC116 NUjscIloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\YfpFKSzVyPUCuNFAzQDlizszN M4LVXHNCVkeHUh?=
RKO M{XEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMECyPVgh|ryP NYHtUmY1W0GQR1XS
MRK-nu-1 M2Xvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHsTWM2OD1yLkCwNlk6KM7:TR?= MoDQV2FPT0WU
VA-ES-BJ NUnjfZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD1yLkCwN{DPxE1? NYD5[Zh1W0GQR1XS
KALS-1 NFfR[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMECzNFgh|ryP MYDTRW5ITVJ?
BB30-HNC NUfMO5BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TjcGlEPTB;MD6wNFMyPCEQvF2= MojlV2FPT0WU
ACN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLZ2JIUUN3ME2wMlAxOzF4IN88US=> MXPTRW5ITVJ?
TE-9 NGr3cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMECzNlYh|ryP M3H5dHNCVkeHUh?=
SIG-M5 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMECzNlch|ryP NYTsOpRbW0GQR1XS
no-10 Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMECzOlIh|ryP M1jxSHNCVkeHUh?=
EW-1 M33PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fQSWlEPTB;MD6wNFM4OSEQvF2= NGTBR2VUSU6JRWK=
SK-LMS-1 M4LyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m1XGlEPTB;MD6wNFQxOSEQvF2= NVvifY9KW0GQR1XS
GT3TKB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnweYxKSzVyPUCuNFA1OzRizszN MX\TRW5ITVJ?
ES4 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnWOWNPUUN3ME2wMlAxPDR7IN88US=> MXnTRW5ITVJ?
IMR-5 NIXEU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEC0OUDPxE1? M17VZnNCVkeHUh?=
NCI-H1648 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEC0Olkh|ryP MmT6V2FPT0WU
MV-4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHBNpVKSzVyPUCuNFA1PzVizszN NIm2fWxUSU6JRWK=
SK-UT-1 M1rofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3YNGJKSzVyPUCuNFA1QCEQvF2= MWXTRW5ITVJ?
NB13 NX\CSINWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33oZWlEPTB;MD6wNFQ6OSEQvF2= NI[1Tm9USU6JRWK=
DJM-1 NFnWSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTXN|hSUUN3ME2wMlAxPTNizszN MkPjV2FPT0WU
ES8 M17HSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fzUmlEPTB;MD6wNFU{QCEQvF2= NIPtSXpUSU6JRWK=
TE-6 NH;IcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zFbmlEPTB;MD6wNFU4KM7:TR?= NVHCWIJjW0GQR1XS
KS-1 NV7nclBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T0N2lEPTB;MD6wNFU5OiEQvF2= M4D3NXNCVkeHUh?=
TE-1 NWrNXYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6TWM2OD1yLkCwOlA3KM7:TR?= NV3oSmNJW0GQR1XS
ATN-1 M3v6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nwVmlEPTB;MD6wNFYxQSEQvF2= M4TwSXNCVkeHUh?=
A4-Fuk NGXs[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHGSZlIUUN3ME2wMlAxPjFzIN88US=> NELzSGVUSU6JRWK=
ALL-PO NXzVfHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7RflFTUUN3ME2wMlAxPjNizszN NUjVcWNFW0GQR1XS
BE-13 M4nzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;NZmlEPTB;MD6wNFY{PiEQvF2= MkDDV2FPT0WU
KM12 NYDY[mpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\n[ll2UUN3ME2wMlAxPjN5IN88US=> M3u4cHNCVkeHUh?=
NOS-1 M3PNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\qNWlEPTB;MD6wNFY2KM7:TR?= NYLUbo9RW0GQR1XS
SW962 NXrvSmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF70cHZKSzVyPUCuNFA3PjJizszN M1\FXnNCVkeHUh?=
OCUB-M NYC0TFhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jx[2lEPTB;MD6wNFY3OiEQvF2= NHL1eZNUSU6JRWK=
NCI-H510A Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEC2OlUh|ryP Mn3kV2FPT0WU
EW-16 NV7MUItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPkTWM2OD1yLkCwOlk1KM7:TR?= M33iVnNCVkeHUh?=
KGN NWXW[ZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3iTWM2OD1yLkCwO|EzKM7:TR?= M{\GPHNCVkeHUh?=
LS-411N NV3mNmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjVOphKSzVyPUCuNFA4OTdizszN M4HZR3NCVkeHUh?=
Becker NWr4RXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\vTWM2OD1yLkCwO|Ih|ryP M1rpN3NCVkeHUh?=
HC-1 NEXXOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Pmb2lEPTB;MD6wNFczOSEQvF2= NF\G[3hUSU6JRWK=
CESS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVviV5Q6UUN3ME2wMlAxPzN5IN88US=> NYDNfHBCW0GQR1XS
KURAMOCHI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO5XXhVUUN3ME2wMlAxPzR6IN88US=> NFzuc3VUSU6JRWK=
TGBC24TKB M2jCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSzUYNkUUN3ME2wMlAxPzV{IN88US=> NWXZ[21wW0GQR1XS
SW982 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;sS2lEPTB;MD6wNFc3PiEQvF2= NIf2TmhUSU6JRWK=
HCE-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnNOpEzUUN3ME2wMlAxPzZ5IN88US=> MmH6V2FPT0WU
LOUCY NE\USlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WxSWlEPTB;MD6wNFc4PSEQvF2= M2PJRnNCVkeHUh?=
8-MG-BA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35W417UUN3ME2wMlAxPzl4IN88US=> M1rDPXNCVkeHUh?=
HT-144 M17xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M336OGlEPTB;MD6wNFgh|ryP NV;6NZUzW0GQR1XS
LXF-289 NWPFTlZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[1SFRHUUN3ME2wMlAxQDF6IN88US=> NI\DU3VUSU6JRWK=
RS4-11 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfYTWM2OD1yLkCwPFM3KM7:TR?= NWfWNm9qW0GQR1XS
DEL NH;1[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLaUVFKSzVyPUCuNFA5PDVizszN Mn\nV2FPT0WU
OCI-AML2 NGOyO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\KfmlEPTB;MD6wNFg2OiEQvF2= MoXPV2FPT0WU
CCRF-CEM M1i0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fsUmlEPTB;MD6wNFg4OSEQvF2= MV\TRW5ITVJ?
A388 M2HqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfn[Jk2UUN3ME2wMlAxQDd2IN88US=> MlL5V2FPT0WU
KNS-42 M1O0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3jTWM2OD1yLkCwPFkyKM7:TR?= NFXUb2RUSU6JRWK=
OVCAR-4 M3rGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHFTWM2OD1yLkCwPVA1KM7:TR?= NG\Lb2ZUSU6JRWK=
NCI-H1355 NHq2Z|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEC5NVQh|ryP MkXZV2FPT0WU
BL-70 NHzhb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrlbFJKSzVyPUCuNFA6OyEQvF2= MV\TRW5ITVJ?
BL-41 NGnv[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\UfFlvUUN3ME2wMlAxQTN2IN88US=> M2rTOXNCVkeHUh?=
A101D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP0fIFUUUN3ME2wMlAxQTZizszN M4PYenNCVkeHUh?=
HL-60 NWPTU4N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzGeXpKSzVyPUCuNFA6PjZizszN NFzT[nRUSU6JRWK=
COR-L279 MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjaOIZxUUN3ME2wMlAxQTl7IN88US=> M2LzbXNCVkeHUh?=
NCI-SNU-16 NVn2R5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[1PYtHUUN3ME2wMlAyODB6IN88US=> MlfSV2FPT0WU
Calu-6 M1jDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLPTWM2OD1yLkCxNFEzKM7:TR?= NHn1b2xUSU6JRWK=
SR NUHwbIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn74TWM2OD1yLkCxNFI3KM7:TR?= NVz2c45FW0GQR1XS
QIMR-WIL NHzCPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TUXGlEPTB;MD6wNVA{OyEQvF2= MYnTRW5ITVJ?
LB647-SCLC M17BV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\YPFZKSzVyPUCuNFExPTFizszN M1y5WnNCVkeHUh?=
RPMI-8226 M{P1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PtR2lEPTB;MD6wNVExOiEQvF2= MX\TRW5ITVJ?
SK-PN-DW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TvR2lEPTB;MD6wNVEyOiEQvF2= M2nxTHNCVkeHUh?=
SF268 M4PLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjKUG9KSzVyPUCuNFEyPTFizszN M1\xO3NCVkeHUh?=
HD-MY-Z MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fzTmlEPTB;MD6wNVE3OyEQvF2= MXPTRW5ITVJ?
DOHH-2 NVi1fVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nCeWlEPTB;MD6wNVIxOyEQvF2= NHHJ[3VUSU6JRWK=
SCC-3 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q1fGlEPTB;MD6wNVIxPCEQvF2= MXvTRW5ITVJ?
ST486 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOwTIFKSzVyPUCuNFEzODRizszN MkDlV2FPT0WU
NALM-6 NVu3blRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv2XIt{UUN3ME2wMlAyOjF2IN88US=> MY\TRW5ITVJ?
NCI-H1436 NV\adIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfkO41RUUN3ME2wMlAyOjNzIN88US=> M2PnfnNCVkeHUh?=
KE-37 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrpTWM2OD1yLkCxNlM1KM7:TR?= MXrTRW5ITVJ?
RPMI-8402 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHCdmF{UUN3ME2wMlAyOjV4IN88US=> NVrBcGJ{W0GQR1XS
RXF393 NHz5[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OxNWlEPTB;MD6wNVI2PyEQvF2= NYHWV4VNW0GQR1XS
KARPAS-45 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[ye2lEPTB;MD6wNVI4KM7:TR?= NXvLWopIW0GQR1XS
HOP-62 NEXYV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOwTWM2OD1yLkCxNlc3KM7:TR?= M{jx[nNCVkeHUh?=
ES1 NH7L[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T4PWlEPTB;MD6wNVI5QCEQvF2= MnjkV2FPT0WU
L-363 NEHvV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX4V3JKSzVyPUCuNFE{PTFizszN NGnVPGVUSU6JRWK=
GI-1 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7XUXpuUUN3ME2wMlAyOzd|IN88US=> MkS3V2FPT0WU
CTV-1 M1zFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWwV|BIUUN3ME2wMlAyPDd6IN88US=> NGjQWFBUSU6JRWK=
TE-5 NFW1OmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrZR|RKSzVyPUCuNFE1QTZizszN NFn1OndUSU6JRWK=
SNU-C2B MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rBdmlEPTB;MD6wNVQ6PiEQvF2= M1nSNXNCVkeHUh?=
K-562 NHXUeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH76OnBKSzVyPUCuNFE2OTZizszN M1HnOXNCVkeHUh?=
SNB75 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonyTWM2OD1yLkCxOVQh|ryP NVfWb3lSW0GQR1XS
MOLT-13 NGjGc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXwTWM2OD1yLkCxOlM4KM7:TR?= NXOwOlU3W0GQR1XS
LS-123 NXLVeHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zm[WlEPTB;MD6wNVY3PCEQvF2= M4DxSHNCVkeHUh?=
NCI-SNU-5 NXK0WmVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZTWM2OD1yLkCxO|AyKM7:TR?= M3fKZnNCVkeHUh?=
Daudi NEnaOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3oVm1IUUN3ME2wMlAyPzB6IN88US=> M2XVNnNCVkeHUh?=
A253 NWLaUWJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvnT2hEUUN3ME2wMlAyPzN6IN88US=> NFjMWo1USU6JRWK=
TGBC1TKB NYO4eIJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTuT|U3UUN3ME2wMlAyPzV{IN88US=> MV;TRW5ITVJ?
SJSA-1 NX30UoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;ETWM2OD1yLkCxO|Y4KM7:TR?= MmniV2FPT0WU
NCCIT MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXJNoRKSzVyPUCuNFE4PjlizszN NX3WVpdtW0GQR1XS
NCI-H69 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEG3O|gh|ryP NGXvPWNUSU6JRWK=
SH-4 NVrQflhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS5UGpKSzVyPUCuNFE5QTVizszN MlnXV2FPT0WU
HCC1187 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3sTWM2OD1yLkCxPVI1KM7:TR?= NEn3flhUSU6JRWK=
HCC1599 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXtWnNKSzVyPUCuNFIxOiEQvF2= MUTTRW5ITVJ?
ONS-76 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILWV5BKSzVyPUCuNFIxOzZizszN M{TEcHNCVkeHUh?=
KU812 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nUN2lEPTB;MD6wNlA{QSEQvF2= MV\TRW5ITVJ?
ML-2 NX31SYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMEKwOFch|ryP NFrJUVlUSU6JRWK=
HCE-T MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEKwPVIh|ryP NFS4RlJUSU6JRWK=
NCI-H446 M1TTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Db|RKSzVyPUCuNFIyOTJizszN NH\QRnZUSU6JRWK=
RPMI-6666 NETYc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD1yLkCyNVQ6KM7:TR?= Mnv4V2FPT0WU
MOLT-16 NETnPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHQdZNKSzVyPUCuNFIyPTNizszN NEnRbGtUSU6JRWK=
JiyoyeP-2003 NXj0Z|A{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfyU2RCUUN3ME2wMlAzOTd4IN88US=> M2rmVnNCVkeHUh?=
MHH-PREB-1 M1z3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn0TWM2OD1yLkCyNVkyKM7:TR?= MUnTRW5ITVJ?
MC-CAR NWOwfHhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jZNGlEPTB;MD6wNlMzPiEQvF2= Mme3V2FPT0WU
BC-3 NULCW2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjq[odKSzVyPUCuNFI{PDRizszN M3vVfHNCVkeHUh?=
KINGS-1 M2rjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEKzOVUh|ryP M4Dmd3NCVkeHUh?=
PF-382 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjFTWM2OD1yLkCyN|c5KM7:TR?= MmnFV2FPT0WU
J-RT3-T3-5 NH7DUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X2VGlEPTB;MD6wNlM5OyEQvF2= NHHucmtUSU6JRWK=
SF539 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEK0NFEh|ryP MnfsV2FPT0WU
LB831-BLC MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEK0PFUh|ryP NGrMW2hUSU6JRWK=
DMS-114 NFnPVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;PUWVKSzVyPUCuNFI2ODJizszN NHH3fVNUSU6JRWK=
LB1047-RCC MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;jTWM2OD1yLkCyOVEh|ryP NUXTPWw2W0GQR1XS
LB771-HNC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PSOmlEPTB;MD6wNlU{PCEQvF2= M3G4SHNCVkeHUh?=
BB65-RCC M1H4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEK1N|Qh|ryP NGX3c2pUSU6JRWK=
BV-173 NWqyN49wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXlfYNKSzVyPUCuNFI2PTRizszN MYjTRW5ITVJ?
ARH-77 NWjs[ZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEK2NFEh|ryP MlrEV2FPT0WU
IST-MEL1 M3vXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnhbJRPUUN3ME2wMlAzPjJ|IN88US=> MWjTRW5ITVJ?
NB1 NVHrRVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEK2PFch|ryP Mmj1V2FPT0WU
EoL-1-cell MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrhdoRKSzVyPUCuNFI3QDhizszN Mn7pV2FPT0WU
KY821 NF\0W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HuemlEPTB;MD6wNlY6PyEQvF2= NIX1NmRUSU6JRWK=
CMK NYrHUWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEK3N|Qh|ryP NYXlNG1bW0GQR1XS
NCI-H2126 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEK3Olgh|ryP MXXTRW5ITVJ?
NCI-H526 NFTJSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEK4PVEh|ryP NYDINHN4W0GQR1XS
COLO-684 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7MUIt1UUN3ME2wMlAzQTB6IN88US=> NXTTXGZzW0GQR1XS
NCI-H747 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfUTWM2OD1yLkCyPVM{KM7:TR?= NGj6T21USU6JRWK=
JAR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[5NpVKSzVyPUCuNFI6PDZizszN MV7TRW5ITVJ?
MEG-01 NVHLb2VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWzTHplUUN3ME2wMlAzQTd6IN88US=> Mlq5V2FPT0WU
MONO-MAC-6 M4XSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeyPW1KSzVyPUCuNFMxOjNizszN NX\WZVZIW0GQR1XS
IST-SL1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEOwOFIh|ryP Mlr5V2FPT0WU
CPC-N NYjGUJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjRTWM2OD1yLkCzNFc6KM7:TR?= NXTqSnF6W0GQR1XS
NCI-H1963 M3nBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrOZY1lUUN3ME2wMlA{OTNzIN88US=> M1\pfXNCVkeHUh?=
K052 NHTVR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnNPXdKSzVyPUCuNFMzPDdizszN NYXqWVJZW0GQR1XS
KM-H2 NIPQVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEOzNFch|ryP NHPu[FhUSU6JRWK=
TE-12 NVTVN4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTIZYFvUUN3ME2wMlA{OzB7IN88US=> MWLTRW5ITVJ?
TK10 NHzObHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzOXZBKSzVyPUCuNFM{PTZizszN M{XUWXNCVkeHUh?=
NMC-G1 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEO0OVIh|ryP Mkm2V2FPT0WU
no-11 NYrGVWxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnxTWM2OD1yLkCzOFc5KM7:TR?= MniyV2FPT0WU
NCI-H524 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPJ[YpKSzVyPUCuNFM2OjlizszN Mn;JV2FPT0WU
MHH-CALL-2 M2DGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEO1OlIh|ryP M1fpXnNCVkeHUh?=
GB-1 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\hZ2lEPTB;MD6wN|Yh|ryP M1vafnNCVkeHUh?=
OPM-2 NHvWO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\nSpZKSzVyPUCuNFM3PzNizszN MYPTRW5ITVJ?
RH-1 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMEO4NVkh|ryP M3XobXNCVkeHUh?=
NCI-H64 NXn2Nm04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTITWM2OD1yLkCzPFU4KM7:TR?= M1;PbXNCVkeHUh?=
EVSA-T M1SzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzQTWM2OD1yLkCzPVI{KM7:TR?= NF7hNFNUSU6JRWK=
KARPAS-299 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjKNmxKSzVyPUCuNFM6QCEQvF2= NFX3TXRUSU6JRWK=
MZ7-mel M1HCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL3TWM2OD1yLkC0NFQh|ryP NV;Jb29mW0GQR1XS
LB373-MEL-D M{TzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;yelBiUUN3ME2wMlA1OTB3IN88US=> NUXw[|Z2W0GQR1XS
HEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHoTWM2OD1yLkC0NVQh|ryP MVvTRW5ITVJ?
SW872 NWfsVGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X6RWlEPTB;MD6wOFIyKM7:TR?= Mn7hV2FPT0WU
DU-4475 NEPEUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j2SmlEPTB;MD6wOFI1PCEQvF2= NXriXWd6W0GQR1XS
IST-SL2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDrTWM2OD1yLkC0Nlc2KM7:TR?= NUnGNIQ5W0GQR1XS
NCI-H82 NHjCV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1yLkC0N|A4KM7:TR?= M3vHV3NCVkeHUh?=
LC4-1 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1naVmlEPTB;MD6wOFM2OSEQvF2= Mof0V2FPT0WU
HDLM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMESzPVIh|ryP M3\QPXNCVkeHUh?=
MMAC-SF NGfFW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O2WWlEPTB;MD6wOFU{PCEQvF2= NHjpOJNUSU6JRWK=
L-540 MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j2OGlEPTB;MD6wOFY{QSEQvF2= MXHTRW5ITVJ?
MZ2-MEL MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfYfHFKSzVyPUCuNFQ4PDJizszN M2fXT3NCVkeHUh?=
LU-134-A NVfEfpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknyTWM2OD1yLkC0O|c{KM7:TR?= NGnlcI1USU6JRWK=
UACC-257 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jPe2lEPTB;MD6wOFg1QSEQvF2= MlPoV2FPT0WU
NCI-H1581 NV;jZVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknLTWM2OD1yLkC0PVU{KM7:TR?= NFGxRo9USU6JRWK=
NB17 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGwNFNHUUN3ME2wMlA1QTd7IN88US=> NXux[lVFW0GQR1XS
SBC-1 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLOTo5JUUN3ME2wMlA2ODR{IN88US=> M1rYTHNCVkeHUh?=
TALL-1 M33YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEWwOFUh|ryP M1z2[nNCVkeHUh?=
NCI-H1304 M2Oz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPxOJpkUUN3ME2wMlA2OjB6IN88US=> NGXZOlVUSU6JRWK=
NEC8 NHfIc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT0TWM2OD1yLkC1Nlg3KM7:TR?= MYnTRW5ITVJ?
CAL-148 M4LTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnLTWM2OD1yLkC1OFM6KM7:TR?= NXXReYhZW0GQR1XS
CGTH-W-1 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;EN|JrUUN3ME2wMlA2PDR7IN88US=> NYXJT3BvW0GQR1XS
NCI-H889 NHH0[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PnTGlEPTB;MD6wOVU6OiEQvF2= MWTTRW5ITVJ?
GR-ST M3TLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEW2NlEh|ryP M2XydHNCVkeHUh?=
KARPAS-422 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzrcIw2UUN3ME2wMlA2PjVizszN M1jjbXNCVkeHUh?=
RPMI-8866 NFi2[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe0OXV3UUN3ME2wMlA2PzF{IN88US=> MoW5V2FPT0WU
SCLC-21H M1;tN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEW4PFQh|ryP M33ETXNCVkeHUh?=
COR-L88 NGjkUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjFUFIyUUN3ME2wMlA2QTJ5IN88US=> NH3te2hUSU6JRWK=
LU-139 M2HjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;QXJVnUUN3ME2wMlA2QTh4IN88US=> MoroV2FPT0WU
SF126 M1\rNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfFVHVKSzVyPUCuNFYyOzNizszN MX\TRW5ITVJ?
NCI-H1882 NV;PWWpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\lTWM2OD1yLkC2OFI1KM7:TR?= NWntPZVWW0GQR1XS
EW-24 NHjicFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwME[0PFMh|ryP Mm\iV2FPT0WU
CP67-MEL MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;zfmZzUUN3ME2wMlA3QDFizszN NFjtWGRUSU6JRWK=
DG-75 NYLodoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fMS2lEPTB;MD6wOlg6QSEQvF2= NGKzeXJUSU6JRWK=
LOXIMVI MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzOdFZKSzVyPUCuNFcxOjhizszN MWPTRW5ITVJ?
HH M13SSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[xN2lEPTB;MD6wO|E2PyEQvF2= NFqxbI1USU6JRWK=
K5 NHqzXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vXSWlEPTB;MD6wO|IzPiEQvF2= NHizfldUSU6JRWK=
EC-GI-10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkO5JLUUN3ME2wMlA4OjV5IN88US=> MlTvV2FPT0WU
SK-N-DZ NXvVT41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfhWVRTUUN3ME2wMlA4OzB5IN88US=> MVnTRW5ITVJ?
A3-KAW NXfrcVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEezOVEh|ryP MkLwV2FPT0WU
MLMA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6ZYtJUUN3ME2wMlA4PDZ3IN88US=> NH\idJRUSU6JRWK=
LB996-RCC NX7Rb5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vObWlEPTB;MD6wO|cxPyEQvF2= MknYV2FPT0WU
OS-RC-2 MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDPO|NKSzVyPUCuNFc4PDhizszN NEDRdWNUSU6JRWK=
CTB-1 M3yxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEe4NUDPxE1? MX\TRW5ITVJ?
IST-MES1 NXnC[5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;MXGlEPTB;MD6wO|kyOiEQvF2= NGTyVm1USU6JRWK=
LS-1034 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\NRpdiUUN3ME2wMlA5ODN3IN88US=> MYrTRW5ITVJ?
HT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqwZWNKSzVyPUCuNFgxQDZizszN M1;HTXNCVkeHUh?=
NCI-H2141 M4L0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSUGlEPTB;MD6wPFEh|ryP NITCcoxUSU6JRWK=
LB2518-MEL M1nidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4XHgyUUN3ME2wMlA5OTRzIN88US=> MVHTRW5ITVJ?
GI-ME-N NGC3PIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEi0OVIh|ryP MnvFV2FPT0WU
TGW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13MPGlEPTB;MD6wPFYxPyEQvF2= MUjTRW5ITVJ?
SK-NEP-1 NHvyfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LzPGlEPTB;MD6wPFY1OSEQvF2= Mmf6V2FPT0WU
NOMO-1 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXYdYtbUUN3ME2wMlA6Ojd3IN88US=> MX\TRW5ITVJ?
ES6 M1\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEm1PFkh|ryP NFi2dG1USU6JRWK=
NCI-H209 NXq0N4UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G0UWlEPTB;MD6wPVc5PiEQvF2= NW\OcGV5W0GQR1XS
GAK NVrYeZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:xTWM2OD1yLkGwNVYh|ryP M4PZenNCVkeHUh?=
BC-1 NYi3TmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGTWM2OD1yLkGwN|YyKM7:TR?= MYnTRW5ITVJ?
KLE MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInSeIZKSzVyPUCuNVA1PDNizszN MXTTRW5ITVJ?
EW-3 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUC5PEDPxE1? NYqwWZJTW0GQR1XS
NKM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj2fnhoUUN3ME2wMlEyOSEQvF2= M3PsVnNCVkeHUh?=
D-336MG MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMUGyOFQh|ryP NVXN[HM3W0GQR1XS
NB69 NWGzOGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu3TWM2OD1yLkGxN|AyKM7:TR?= M3PYUnNCVkeHUh?=
D-263MG NGHnNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW1TWM2OD1yLkGxO|EzKM7:TR?= M2TTXHNCVkeHUh?=
KP-N-YS NEfv[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUKyPVEh|ryP NGXkW5ZUSU6JRWK=
NCI-H1155 NXTu[FgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXUSnZ4UUN3ME2wMlEzPTV6IN88US=> MlfiV2FPT0WU
BOKU MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nTeGlEPTB;MD6xNlU4QSEQvF2= NUfLXFJnW0GQR1XS
LAMA-84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DkUmlEPTB;MD6xNlk6KM7:TR?= NVPxPIZuW0GQR1XS
Raji NIDUOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jxfWlEPTB;MD6xN|EyPyEQvF2= MoDIV2FPT0WU
LU-65 M{LCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMUOzNFch|ryP MYDTRW5ITVJ?
NCI-H187 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrlU2ROUUN3ME2wMlE{QTJ2IN88US=> NEnVdFNUSU6JRWK=
GCIY NYntOW1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Td2lEPTB;MD6xOFkxOSEQvF2= NVTpcJNjW0GQR1XS
NCI-H2107 NG\Dd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe0TGNKSzVyPUCuNVUxQCEQvF2= MVvTRW5ITVJ?
NCI-H1522 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD6TWM2OD1yLkG1NlY3KM7:TR?= MUPTRW5ITVJ?
NB6 NWS3XWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H2UGlEPTB;MD6xOVYzOyEQvF2= NHrwOYdUSU6JRWK=
EM-2 M4jCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XUVGlEPTB;MD6xOVcxPiEQvF2= M4\SeHNCVkeHUh?=
HCC2218 NVjibXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;lOIJKSzVyPUCuNVU6QCEQvF2= MVPTRW5ITVJ?
NCI-H748 NGTGbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED5ZVVKSzVyPUCuNVY{PzZizszN MUDTRW5ITVJ?
MS-1 NIL1NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXYemNnUUN3ME2wMlE3PTN5IN88US=> NXrk[ow4W0GQR1XS
NB5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMU[1PVch|ryP M3zuZXNCVkeHUh?=
OMC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXK[HNLUUN3ME2wMlE3Pjh6IN88US=> MY\TRW5ITVJ?
NCI-H345 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63UmxMUUN3ME2wMlE3QTJ6IN88US=> NX[3bVhOW0GQR1XS
L-428 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\pRpBKSzVyPUCuNVY6PDVizszN M{fNTHNCVkeHUh?=
SCH M2S2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMUi2PFUh|ryP MmT4V2FPT0WU
NCI-H1417 NUmzfoYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M331WGlEPTB;MD6xPVIzPyEQvF2= M{\mcHNCVkeHUh?=
COLO-320-HSR NHizSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vxb2lEPTB;MD6xPVU{OiEQvF2= NGOxT3FUSU6JRWK=
BT-474 NH7xPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMkC4PVIh|ryP M3TyfXNCVkeHUh?=
GDM-1 M2rqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3TWM2OD1yLkKxPVcyKM7:TR?= MVLTRW5ITVJ?
NCI-H2196 M4LFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfaU2hzUUN3ME2wMlIzOjN3IN88US=> NHeyWopUSU6JRWK=
KP-N-RT-BM-1 NITvbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon2TWM2OD1yLkKyN|Q6KM7:TR?= MVnTRW5ITVJ?
KNS-81-FD NVLHbWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMkK5OVgh|ryP NEXqZYlUSU6JRWK=
COLO-668 M1LVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\SdHBjUUN3ME2wMlI{Pjd3IN88US=> MXjTRW5ITVJ?
C2BBe1 NGD2cHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j2RWlEPTB;MD6yOlc1PyEQvF2= MlHKV2FPT0WU
Ramos-2G6-4C10 NGrscoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XKemlEPTB;MD6yOlk2PCEQvF2= NHzLPWtUSU6JRWK=
CAS-1 NX3TXm9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMkewPVYh|ryP MVjTRW5ITVJ?
GOTO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO5UpNKSzVyPUCuNlc5QTRizszN NGHxT3hUSU6JRWK=
LP-1 M3Lz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvXcoNzUUN3ME2wMlI5ODV5IN88US=> NXHyRnRjW0GQR1XS
NCI-SNU-1 NUnvT4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzsUYNKSzVyPUCuNlk1OjJizszN NIDacYpUSU6JRWK=
EB-3 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z4WmlEPTB;MD6yPVk4QSEQvF2= NHK1cFlUSU6JRWK=
MHH-NB-11 NIT0dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC2NXRKSzVyPUCuN|A1ODJizszN NIjOZ3dUSU6JRWK=
SK-N-FI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7pTWM2OD1yLkOxOlkzKM7:TR?= NUfwe5prW0GQR1XS
HCC2157 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj5b2VKSzVyPUCuN|M6OTNizszN NEHH[XFUSU6JRWK=
SIMA MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDIV2RHUUN3ME2wMlM1PThzIN88US=> Mo[4V2FPT0WU
MDA-MB-134-VI MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\2SIJKSzVyPUCuN|Y6OjhizszN MkfnV2FPT0WU
NCI-H1694 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmxTWM2OD1yLkO3JO69VQ>? NH3zRXVUSU6JRWK=
EHEB NFi3SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zYTmlEPTB;MD6zPVA5PSEQvF2= M4\lNHNCVkeHUh?=
U-266 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorFTWM2OD1yLkO5PFQ3KM7:TR?= NViwZ49[W0GQR1XS
LC-1F M3XnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPkVJJRUUN3ME2wMlQ{PzZ3IN88US=> MoLWV2FPT0WU
SHP-77 M2fZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHz[FdKSzVyPUCuOFc5PTVizszN M4rKW3NCVkeHUh?=
LS-513 NE\1VoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj1OJFKSzVyPUCuOFk{ODdizszN Mnj1V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694002 Recruiting Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) August 9 2018 Phase 2
NCT03275818 Recruiting Tumor Desmoplastic Small Round Cell Adult|Tumor Desmoplastic Small Round Cell Childhood|Sarcoma Ewing|Sarcoma|Desmoid Grupo Espanol de Investigacion en Sarcomas May 9 2017 Phase 2
NCT03057600 Active not recruiting Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer Calithera Biosciences Inc May 9 2017 Phase 2
NCT02775435 Active not recruiting Non-small Cell Lung Cancer Merck Sharp & Dohme Corp. June 9 2016 Phase 3
NCT02181634 Completed Cholangiocarcinoma PrECOG LLC.|Celgene Corporation December 9 2014 Phase 2
NCT02415023 Completed Gastric Cancer Hutchison Medipharma Limited November 9 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID